Glenn H. Nussdorf - 16 Dec 2025 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role: Director
Signature: /s/ William R. Kolb, Attorney-in-Fact
Issuer symbol: ORGO
Transactions as of: 16 Dec 2025
Net transactions value: -$1,027,060
Form type: 4
Filing time: 18 Dec 2025, 16:19:19 UTC
Previous filing: 26 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
NUSSDORF GLENN H	Director	35 SAWGRASS DRIVE, BELLPORT	/s/ William R. Kolb, Attorney-in-Fact	18 Dec 2025	0001244191

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ORGO	Class A Common Stock	Sale	$1,027,060	-200,000	-7.2%	$5.14	2,565,591	16 Dec 2025	Direct	F1
holding	ORGO	Class A Common Stock						918,680	16 Dec 2025	By GN 2016 Family Trust u/a/d August 12, 2016
holding	ORGO	Class A Common Stock						7,928,570	16 Dec 2025	By GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016
holding	ORGO	Class A Common Stock						335,719	16 Dec 2025	By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.24, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.24, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.